Skip to main content

The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review.

Publication ,  Journal Article
Vanden Berg, RNW; Zilli, T; Achard, V; Dorff, T; Abern, M
Published in: Prostate Cancer Prostatic Dis
December 2023

BACKGROUND: Oligometastatic prostate cancer (OMPCa) is emerging as a transitional disease state between localized and polymetastatic disease. This review will assess the current knowledge of castrate-sensitive OMPCa. METHODS: A review of the current literature was performed to summarize the definition and classification of OMPCa, assess the diagnostic methods and imaging modalities utilized, and to review the treatment options and outcomes. We further identify gaps in knowledge and areas for future research. RESULTS: Currently there is no unified definition of OMPCa. National guidelines mostly recommend systemic therapies without distinguishing oligometastatic and polymetastatic disease. Next generation imaging is more sensitive than conventional imaging and has led to early detection of metastases at initial diagnosis or recurrence. While mostly retrospective in nature, recent studies suggest that treatment (surgical or radiation) of the primary tumor and/or metastatic sites might delay initiation of androgen deprivation therapy while increasing survival in selected patients. CONCLUSIONS: Prospective data are required to better assess the incremental improvement in survival and quality of life achieved with various treatment strategies in patients with OMPCa.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

December 2023

Volume

26

Issue

4

Start / End Page

702 / 711

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Retrospective Studies
  • Quality of Life
  • Prostatic Neoplasms
  • Prospective Studies
  • Male
  • Humans
  • Androgen Antagonists
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vanden Berg, R. N. W., Zilli, T., Achard, V., Dorff, T., & Abern, M. (2023). The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review. Prostate Cancer Prostatic Dis, 26(4), 702–711. https://doi.org/10.1038/s41391-023-00688-w
Vanden Berg, Rand N Wilcox, Thomas Zilli, Vérane Achard, Tanya Dorff, and Michael Abern. “The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review.Prostate Cancer Prostatic Dis 26, no. 4 (December 2023): 702–11. https://doi.org/10.1038/s41391-023-00688-w.
Vanden Berg RNW, Zilli T, Achard V, Dorff T, Abern M. The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review. Prostate Cancer Prostatic Dis. 2023 Dec;26(4):702–11.
Vanden Berg, Rand N. Wilcox, et al. “The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review.Prostate Cancer Prostatic Dis, vol. 26, no. 4, Dec. 2023, pp. 702–11. Pubmed, doi:10.1038/s41391-023-00688-w.
Vanden Berg RNW, Zilli T, Achard V, Dorff T, Abern M. The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review. Prostate Cancer Prostatic Dis. 2023 Dec;26(4):702–711.

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

December 2023

Volume

26

Issue

4

Start / End Page

702 / 711

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Retrospective Studies
  • Quality of Life
  • Prostatic Neoplasms
  • Prospective Studies
  • Male
  • Humans
  • Androgen Antagonists
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences